This analysis examines the historical and forecast performance for Merck & Co. in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
* Gain insight into Merck & Co.'s strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Merck & Co. over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
* Benchmark Merck & Co.'s performance against key rivals in the prescription pharmaceutical sector.* Assess the continued commercial and strategic impact of Merck & Co.'s 2009 acquisition of Schering-Plough.*
------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/
------------------------------------------------------------
Partial Table of Contents:
TABLE OF CONTENTS
ABOUT DATAMONITOR HEALTHCARE
About the PharmaVitae team
Chapter 1 About this profile
PharmaVitae Explorer database
Chapter structure
Data sourcing
Chapter 2 Executive summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003-15
Financial performance, 2003-15
Merck & Co.: PharmaVitae forecasts at a glance
Strategic insight
SWOT analysis
Chapter 3 Quarterly news update
Latest quarterly sales
Latest quarterly financial analysis
Latest comment
Latest prescription pharma product news
Latest corporate news
Future product milestones
Chapter 4 Company introduction
Key findings
Background
Key corporate developments
Chapter 5 Company sales
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003-15
Product analysis
Therapy area analysis
Geographic analysis
Launch/core/
Molecule type analysis
Externalization analysis
Chapter 6 Company financials
Key findings
Reconciliation between PharmaVitae-
Operating costs and profit analysis
Chapter 7 Key products
Overview
Chapter 8 Appendix
References
Abbreviations
Exchange rates
About Datamonitor
Datamonitor consulting
Disclaimer
TABLE OF TABLES
Table 1: Merck & Co. - PharmaVitae forecasts at a glance
Table 2: Big Pharma peer set ranked by 2008 prescription pharmaceutical sales
Table 3: Big Pharma peer set sales forecasts($m)
Table 4: New Merck's launching pipeline
Table 5: Merck & Co. quarterly sales ($m), Q309-Q310
Table 6: Merck & Co. quarterly financials ($m), Q309-Q310
Table 7: Merck & Co. future product milestones, 2010-12
Table 8: Merck & Co. product portfolio overview ($m), 2003-09
Table 9: Merck & Co. product portfolio overview ($m), 2009-15
Table 10: Merck & Co. prescription pharmaceutical sales by therapy area ($m), 2009-15
Table 11: Merck & Co. prescription pharmaceutical sales by geographic region ($m), 2009-15
Table 12: Merck & Co. launch portfolio overview ($m), 2009-15
Table 13: Merck & Co. core portfolio overview ($m), 2009-15
Table 14: Merck & Co. expiry portfolio overview ($m), 2009-15
Table 15: Merck & Co. prescription pharmaceutical sales by molecule type ($m), 2009-15
Table 16: Merck & Co. prescription pharmaceutical sales by source ($m), 2009-15
Table 17: Total Merck & Co. sales by business unit ($m), 2003-09
Table 18: Merck & Co. operating revenue/cost analysis ($m), 2003-09
Table 19: Merck & Co. operating cost ratio analysis (% of total revenues), 2003-09
Table 20: Merck & Co. operating cost ratio analysis (% of total revenues), 2009-15
Table 21: Merck & Co. operating revenue/cost analysis ($m), 2009-15
Table 22: Merck & Co. key products overview
Table 23: Januvia: overview
Table 24: Janumet: overview
Table 25: sitagliptin/
Table 26: Januvia: sales forecast ($m), 2009-15
Table 27: Janumet: sales forecast ($m), 2009-15
Table 28: sitagliptin/
Table 29: Total sitagliptin franchise: sales forecast ($m), 2009-15
Table 30: Remicade: overview
Table 31: Simponi: overview
Table 32: Remicade: sales forecast ($m), 2009-15
Table 33: Simponi: sales forecast ($m), 2009-15
Table 34: Isentress: overview
Table 35: Isentress: sales forecast ($m), 2009-15
Table 36: ProQuad/MMRII/
Table 37: ProQuad/MMRII/
Table 38: Singulair: overview
Table 39: Singulair: sales forecast ($m), 2009-15
Table 40: Zetia: overview
Table 41: Vytorin: overview
Table 42: Zetia: sales forecast ($m), 2009-15
Table 43: Vytorin: sales forecast ($m), 2009-15
Table 44: Saphris: overview
Table 45: Saphris: sales forecast ($m), 2009-15
Table 46: Cozaar/Hyzaar:
Table 47: Cozaar/Hyzaar:
Table 48: SCH 530348: overview
Table 49: SCH 530348: sales forecast ($m), 2009-15
Table 50: Exchange rates, 2010
TABLE OF FIGURES
Figure 1: The PharmaVitae Explorer
Full Table of Contents is available at:
-- http://www.fastmr.com/
About Datamonitor
The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
# # #
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
